Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.
about
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvantA Novel Method for Assessment of Natural Killer Cell Cytotoxicity Using Image CytometryCytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2AUltra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factorhI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma.Ontogeny and expansion of human natural killer cells: clinical implications.An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.Prostate-specific membrane antigen-based therapeutics.What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?Autologous immune enhancement therapy: A case report of a stage IV colonic cancer.Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.Effects of simulated microgravity on primary human NK cells.IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patientsUtilizing cytokines to function-enable human NK cells for the immunotherapy of cancer.Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.Natural killer cells as a promising tool to tackle cancer-A review of sources, methodologies, and potentials.Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner.Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect?Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma
P2860
Q24655036-DD2B90FA-130B-4186-9919-6A2A15346454Q27312227-22D8D73C-F951-4D1E-8B53-857848ADBFB5Q28731856-17C5EF7D-CD86-4978-A96A-247C651F7A41Q33870728-697AD968-5A13-46C7-B658-A9DFF902D511Q33938673-8EE49D3B-D4E3-4553-8E50-90ED244B052EQ34253625-E8BEFA49-C751-47FA-AA58-B38337800710Q34552167-3DB81F3F-F767-4AFD-9E27-DC5EAE2FF3C1Q34893862-B2B38DC7-4421-4DB3-B6A6-A1A30125F278Q35132944-E084967E-5643-42C1-843F-5A0EFE1CF3A4Q36396476-2AE6812A-7CA5-42DF-A9BB-28C672CA9F24Q36919283-9DC33D80-062C-449E-9CE7-D52B219EC11DQ36972097-06E21F50-3F8E-41B6-9D17-7D20E73F0DE2Q37101973-5D05A3B4-7034-4AEB-BCF5-1BCD3AD9A31DQ37410551-8229C5AC-CE82-4F11-981E-7FF557EE4740Q38233046-40BDD5D4-D939-4D79-9613-AB8D037023C9Q38353557-769C6E11-BE7E-457B-99A1-747251B7129BQ38687810-D757EB89-4060-4013-AC35-20EEABF27510Q38742863-73EC0794-67B7-49CB-A61E-FA8097FC9AECQ42700000-ADC3BCE6-E886-4776-AC5E-2B60163E6CA8Q43760313-AB41ECA4-54B9-41B5-BF5D-9BE3732E2A3EQ47570438-C4C96E90-7DAB-4413-AA69-82B27F6B332CQ54333652-B7D6100B-886B-441E-B9EF-CC6288992475Q58415142-EF70AC33-8679-40E2-BEBF-8C811B3FBE26
P2860
Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Potential mechanisms of human ...... during low-dose IL-2 therapy.
@ast
Potential mechanisms of human ...... during low-dose IL-2 therapy.
@en
type
label
Potential mechanisms of human ...... during low-dose IL-2 therapy.
@ast
Potential mechanisms of human ...... during low-dose IL-2 therapy.
@en
prefLabel
Potential mechanisms of human ...... during low-dose IL-2 therapy.
@ast
Potential mechanisms of human ...... during low-dose IL-2 therapy.
@en
P2093
P2860
P356
P1476
Potential mechanisms of human ...... during low-dose IL-2 therapy.
@en
P2093
E M Bluman
J B VanDeusen
M A Caligiuri
M A Cooper
M M Porter
S R Frankel
T A Fehniger
P2860
P304
P356
10.1172/JCI6218
P407
P577
2000-07-01T00:00:00Z